20 years of revenue, earnings, cash-flow and balance-sheet history from public filings.
Compass Therapeutics Inc. (CMPX) operates in the BIOTECHNOLOGY industry and is headquartered in Boston, United States with about 39 employees. Its market capitalization is roughly $142 million. In the fiscal year ended 2025-12-31, CMPX reported $0M in revenue and ($66M) in net income.
Compass Therapeutics, Inc., a clinical-stage oncology-focused biopharmaceutical company, develops antibody-based therapeutics for the treatment of various human diseases in the United States.
Interactive charts & full statements →
| Income statement | TTM → 2026-06-30 | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | $0M | $0M | $1M | $0M | $0M | $0M | $0M | $0M | $0M |
| Gross Profit | — | ($1M) | $1M | ($2M) | ($2M) | ($2M) | ($2M) | ($2M) | ($2M) |
| Gross Margin % | — | — | 100.0% | — | — | — | — | — | — |
| Operating Income (EBIT) | ($81M) | ($73M) | ($57M) | ($50M) | ($42M) | ($82M) | ($28M) | ($34M) | ($38M) |
| Operating Margin % | — | — | -6661.8% | — | — | — | — | — | — |
| Net Income | ($73M) | ($66M) | ($49M) | ($42M) | ($39M) | ($82M) | ($30M) | ($35M) | ($38M) |
| Net Margin % | — | — | -5808.8% | — | — | — | — | — | — |
| EBITDA | ($73M) | ($65M) | ($48M) | ($41M) | ($35M) | ($80M) | ($25M) | ($32M) | ($36M) |
| Earnings Per Share (EPS) | $-0.42 | $-0.42 | $-0.36 | $-0.33 | $-0.37 | $-1.31 | $-0.52 | $-0.67 | $-7.66 |
| Shares Outstanding (M) | 187M | 158M | 137M | 127M | 105M | 63M | 56M | — | 5M |
USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).
| Quarterly income statement | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-12-31 | 2024-09-30 |
|---|---|---|---|---|---|---|---|---|
| Total Revenue | $0M | $0M | $0M | $0M | $0M | $0M | $0M | $0M |
| Gross Profit | — | $0M | $0M | — | $0M | — | — | — |
| Gross Margin % | — | — | — | — | — | — | — | — |
| Operating Income (EBIT) | ($27M) | ($20M) | ($18M) | ($16M) | ($21M) | ($18M) | ($17M) | ($12M) |
| Operating Margin % | — | — | — | — | — | — | — | — |
| Net Income | ($25M) | ($18M) | ($16M) | ($14M) | ($20M) | ($17M) | ($15M) | ($10M) |
| Net Margin % | — | — | — | — | — | — | — | — |
| EBITDA | ($25M) | ($18M) | ($15M) | ($14M) | ($20M) | ($16M) | ($15M) | ($10M) |
| Earnings Per Share (EPS) | $-0.13 | $-0.10 | $-0.09 | $-0.10 | $-0.14 | $-0.12 | $-0.11 | $-0.08 |
| Shares Outstanding (M) | 187M | 186M | 185M | 138M | 138M | 138M | 137M | 138M |
USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).
| Cash flow | TTM → 2026-06-30 | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 |
|---|---|---|---|---|---|---|---|---|---|
| Cash from Operations (CFO) | ($55M) | ($49M) | ($45M) | ($41M) | ($34M) | ($20M) | ($27M) | ($32M) | ($34M) |
| Capital Expenditures (CapEx) | $0M | $0M | $0M | $0M | $0M | $2M | $0M | $0M | $2M |
| Free Cash Flow (FCF) | ($55M) | ($49M) | ($45M) | ($41M) | ($34M) | ($21M) | ($27M) | ($32M) | ($36M) |
| FCF Margin % | — | — | -5282.2% | — | — | — | — | — | — |
USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).
| Quarterly cash flow | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-12-31 | 2024-09-30 |
|---|---|---|---|---|---|---|---|---|
| Cash from Operations (CFO) | ($13M) | ($17M) | ($13M) | ($11M) | ($12M) | ($13M) | ($9M) | ($11M) |
| Capital Expenditures (CapEx) | $0M | $0M | $0M | $0M | $0M | $0M | $0M | $0M |
| Free Cash Flow (FCF) | ($14M) | ($17M) | ($13M) | ($11M) | ($12M) | ($13M) | ($9M) | ($11M) |
| FCF Margin % | — | — | — | — | — | — | — | — |
USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).
| Balance sheet | 2026-06-30 | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 |
|---|---|---|---|---|---|---|---|---|---|
| Total Assets | $190M | $220M | $140M | $157M | $200M | $154M | $52M | $30M | $65M |
| Cash & Cash Equivalents | $35M | $31M | $43M | $24M | $35M | $145M | $47M | $25M | $58M |
| Total Liabilities | $24M | $23M | $15M | $8M | $18M | $14M | $12M | $149M | $149M |
| Total Debt (Short + Long-Term) | $2M | $1M | $0M | $1M | $1M | $1M | $9M | $15M | $15M |
| Total Shareholders' Equity | $166M | $197M | $125M | $149M | $182M | $140M | $40M | ($119M) | ($85M) |
USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).
Quarterly statements, profitability ratios, price history, insider activity and institutional holders are in the interactive CMPX viewer.
About TickerBase · Data methodology & sources · Privacy · Terms